December 2, 2013
Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This “nanosponge vaccine” enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA—both within the bloodstream and on…
August 25, 2015
Nanoengineers at the University of California, San Diego used an innovative 3D printing technology they developed to manufacture multipurpose fish-shaped microrobots — called microfish — that are efficient swimmers, are chemically powered and magnetically controlled. These proof-of-concept synthetic microfish will inspire a new generation of “smart” microrobots that have diverse…
November 6, 2017
A study led by Kevin King, a bioengineer and physician at the University of California San Diego, has found that the immune system plays a surprising role in the aftermath of heart attacks. The research could lead to new therapeutic strategies for heart disease. Researchers present their findings in the…
July 9, 2020
Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.
July 15, 2020
From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.
July 24, 2020
UC San Diego Health and the Altman Clinical and Translational Research Institute will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the coronavirus that causes COVID-19.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
September 2, 2020
UC San Diego Health will be part of the Phase III national AstraZeneca clinical trial that will recruit up to 30,000 participants at multiple sites across the country to assess the safety and efficacy of a vaccine to prevent COVID-19.
October 1, 2020
UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.
November 30, 2020
University of California San Diego has been selected by the NIH to lead and administer an international seven-year, $28-million grant for HIV/AIDS clinical trials.
